Agalsidase-Beta Therapy for Advanced Fabry DiseaseMaryam Banikazemi, Robert J. Desnick, Seymour Packman et al.|Annals of Internal Medicine|2007Cited by 565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, Robert J. Desnick, David G. Warnock et al.|Nephrology Dialysis Transplantation|2009Cited by 366
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Joel Charrow et al.|Journal of Medical Genetics|2015Cited by 363
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroupDominique P. Germain, David G. Warnock, João Paulo Oliveira et al.|Journal of Medical Genetics|2020Cited by 66